GlassScriptPhysician profile
Christopher Barnett Baker
NPI 1609223932
$2,397.07
in general payments reported to CMS, 2019-2025
29 companies · $884 in 2025
The $884 reported for 2025 was more than what 82% of Radiation Oncology providers received nationally (typical 2025 total: $172).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $86.42 · 2022: $36.55 · 2023: $93.14 · 2024: $1,297 · 2025: $884.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,812 · Travel and Lodging: $463.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,811.60 |
| Travel and Lodging | $462.50 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Philips North America LLC | $518.14 | 2024 | (P79) Azurion 7 B20 |
| Janssen Biotech, INC. | $324.82 | 2021-2025 | Tecvayli, Darzalex, Rybrevant |
| Astrazeneca Pharmaceuticals LP | $286.60 | 2024-2025 | Lynparza, Enhertu, Imfinzi |
| Merck Sharp & Dohme LLC | $200.33 | 2024-2025 | Keytruda, Lynparza, Keytruda Qlex |
| Siemens Medical Solutions USA, INC. | $154.15 | 2024-2025 | Aria Radiation Therapy Management Software, Truebeam, Edge |
| Regeneron Healthcare Solutions, INC. | $103.00 | 2024-2025 | Libtayo |
| Genentech USA, INC. | $84.34 | 2024-2025 | Tecentriq, Venclexta, Alecensa |
| Myriad Genetic Laboratories, INC. | $80.42 | 2021-2025 | Prolaris |
| Lilly USA, LLC | $74.81 | 2024 | Verzenio, Retevmo, Jaypirca |
| Stemline Therapeutics INC. | $72.71 | 2024-2025 | Orserdu |
| Daiichi Sankyo INC. | $72.34 | 2025 | Enhertu |
| Jazz Pharmaceuticals INC. | $60.75 | 2025 | |
| Incyte Corporation | $38.30 | 2025 | Monjuvi, Zynyz |
| Novartis Pharmaceuticals Corporation | $36.35 | 2024-2025 | |
| Novocure INC. | $36.14 | 2023-2025 | Optune |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $35.69 | 2025 | |
| Array Biopharma INC | $21.52 | 2024 | Tukysa, Mektovi, Braftovi |
| Pharmaessentia USA Corporation | $21.29 | 2025 | Besremi |
| Blueprint Medicines Corporation | $18.40 | 2024 | Ayvakit |
| Abbvie INC. | $18.30 | 2025 | |
| Aadi Bioscience, INC. | $18.25 | 2025 | Fyarro |
| Adc Therapeutics America, INC. | $18.00 | 2024 | |
| Myovant Sciences INC. | $16.84 | 2021 | |
| Telix Pharmaceuticals | $15.89 | 2023 | Illuccix |
| Celgene Corporation | $15.84 | 2022 | |
| Exelixis INC. | $15.57 | 2024 | |
| Sumitomo Pharma America, INC. | $14.64 | 2024 | Orgovyx |
| Acceleron Pharma, INC. | $11.83 | 2021 | |
| Glaxosmithkline, LLC. | $11.81 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Christopher Baker listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.